Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Vaxart ( (VXRT) ) just unveiled an update.
On May 12, 2025, Vaxart, Inc. issued a press release addressing frequently asked questions about a proposed reverse stock split, which will be voted on at the company’s Annual Meeting on May 21, 2025. The reverse stock split is intended to help Vaxart regain compliance with Nasdaq’s minimum bid price requirement and avoid delisting. The proposal is supported by leading proxy advisory firms, and Vaxart’s board of directors recommends stockholders vote in favor of it. The reverse stock split is seen as a strategic move to maintain Nasdaq listing, potentially increase market visibility, and enhance long-term value, which is crucial for the company’s future growth and financing opportunities.
The most recent analyst rating on (VXRT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
Spark’s Take on VXRT Stock
According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.
Vaxart’s overall score is driven by strong revenue growth and progress in its norovirus vaccine program, providing a positive outlook. However, significant challenges in profitability, cash flow management, and uncertainties in the COVID-19 program weigh heavily on the stock. Technical indicators suggest bearish momentum, while valuation metrics highlight financial struggles. The company’s strategic initiatives and cash management efforts offer some hope for future stability, but current risks remain substantial.
To see Spark’s full report on VXRT stock, click here.
More about Vaxart
Vaxart, Inc. is a biotechnology company based in South San Francisco, California, focusing on developing oral vaccines that are administered by tablet rather than by injection. The company is involved in clinical-stage programs for COVID-19 and norovirus and is advancing a promising preclinical pipeline.
Average Trading Volume: 1,925,071
Technical Sentiment Signal: Sell
Current Market Cap: $95.76M
For a thorough assessment of VXRT stock, go to TipRanks’ Stock Analysis page.